Literature DB >> 1349447

Developments in the drug treatment of schizophrenia.

G P Reynolds1.   

Abstract

Despite its efficacy in many cases, the drug treatment of schizophrenia remains problematic. A substantial proportion of patients do not improve, and many others suffer from unpleasant side-effects. In this review, Gavin Reynolds describes the new approaches to antipsychotic drug development that attempt to address these problems, and relates some of these approaches to growing evidence for neuronal pathology in the brain in schizophrenia.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1349447     DOI： 10.1016/0165-6147(92)90041-4

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  19 in total

Review 1.  Modulation of ligand-gated ion channels by antidepressants and antipsychotics.

Authors:  Gerhard Rammes; Rainer Rupprecht
Journal:  Mol Neurobiol       Date:  2007-04       Impact factor: 5.590

2.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

Review 3.  Behavioural sensitization in addiction, schizophrenia, Parkinson's disease and dyskinesia.

Authors:  W J Schmidt; R J Beninger
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

4.  Trifluoperazine enhancement of Ca2+-dependent inactivation of L-type Ca2+ currents in Helix aspersa neurons.

Authors:  H Cruzblanca; S M Gamiño; J Bernal; F J Alvarez-Leefmans
Journal:  Invert Neurosci       Date:  1998-03

5.  Antagonism of the effects of (+)-PD 128907 on midbrain dopamine neurones in rat brain slices by a selective D2 receptor antagonist L-741,626.

Authors:  B J Bowery; Z Razzaque; F Emms; S Patel; S Freedman; L Bristow; J Kulagowski; G R Seabrook
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

6.  Involvement of dopamine D1 and D2 receptors in the rat nucleus accumbens in immunostimulation.

Authors:  L V Devoino; E L Al'perina; M M Gevorgyan; M A Cheido
Journal:  Neurosci Behav Physiol       Date:  2007-02

7.  Inhibition by various antipsychotic drugs of the G-protein-activated inwardly rectifying K(+) (GIRK) channels expressed in xenopus oocytes.

Authors:  T Kobayashi; K Ikeda; T Kumanishi
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

8.  Chronic clozapine versus chronic haloperidol treatment: differential effects on electrically evoked dopamine efflux in the rat caudate putamen, but not in the nucleus accumbens.

Authors:  K J Feasey-Truger; C Alzheimer; G ten Bruggencate
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-12       Impact factor: 3.000

9.  Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia.

Authors:  Y Noda; K Yamada; H Furukawa; T Nabeshima
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

10.  Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental area.

Authors:  B Bowery; L A Rothwell; G R Seabrook
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.